Reduced risk of disease during postsecondary dengue virus infections

Journal of Infectious Diseases

Volumn 208, Issue 6, 2013, Pages 1026-1033

  Olkowski, Sandra ^a   Forshey, Brett M ^b,d   Morrison, Amy C ^a,d   Rocha, Claudio ^d   Vilcarromero, Stalin ^d   Halsey, Eric S ^d   Kochel, Tadeusz J ^d,e   Scott, Thomas W ^a,c   Stoddard, Steven T ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d California   (Peru)

^e NAVAL MEDICAL RESEARCH CENTER   (United States)

Author keywords

antibody cross protection; dengue; dengue fever; seroepidemiology

Indexed keywords

ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; DENGUE; DENGUE VIRUS 3; DENGUE VIRUS 4; DISEASE SURVEILLANCE; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; PERU; POSTSECONDARY INFECTION; PRIMARY INFECTION; PRIORITY JOURNAL; REINFECTION; RISK REDUCTION; SECONDARY INFECTION; SEROCONVERSION; SEROTYPE; VIRUS NEUTRALIZATION; VIRUS TRANSMISSION;

ANTIBODY CROSS-PROTECTION; DENGUE; DENGUE FEVER; SEROEPIDEMIOLOGY;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; COINFECTION; CROSS PROTECTION; DENGUE; DENGUE VIRUS; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; NEUTRALIZATION TESTS; PERU; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; SEROTYPING;

EID: 84883216648     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit273     Document Type: Article

References (50)

1. World Health Organization. Dengue and dengue hemorrhagic fever. Fact sheet 117. Geneva:World Health Organization, 2012.
2. Brady OJ, Gething PW, Bhatt S, et al. Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLoS Negl Trop Dis 2012; 6:e1760.
3. Simmons CP, Farrar JJ, Chau NV, Wills B. Dengue. N Engl J Med 2012; 366:1423-32.
4. Rothman AL. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nature Rev Immunol 2011; 11:532-43.
5. Whitehorn J, Simmons CP. The pathogenesis of dengue. Vaccine 2011; 29:7221-8.
6. Midgley CM, Flanagan A, Tran HB, et al. Structural analysis of a dengue cross-reactive antibody complexed with envelope domain III reveals the molecular basis of cross-reactivity. J Immunol 2012; 188:4971-9.
7. Dejnirattisai W, Jumnainsong A, Onsirisakul N, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science 2010; 328:745-8.
8. Halstead SB, O'Rourke EJ. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med 1977; 146:201-17.
9. Vaughn DW, Green S, Kalayanarooj S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000; 181:2-9.
10. Gibbons RV, Kalanarooj S, Jarman RG, et al. Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences. Am J Trop Med Hyg 2007; 77:910-3.
11. Adams B, Holmes EC, Zhang C, et al. Cross-protective immunity can account for the alternating epidemic pattern of dengue virus serotypes circulating in Bangkok. Proc Natl Acad Sci USA 2006; 103:14234-9.
12. Cummings DA, Schwartz IB, Billings L, Shaw LB, Burke DS. Dynamic effects of antibody-dependent enhancement on the fitness of viruses. Proc Natl Acad Sci USA 2005; 102:15259-64.
13. Ferguson N, Anderson R, Gupta S. The effect of antibody-dependent enhancement on the transmission dynamics and persistence of multiplestrain pathogens. Proc Natl Acad Sci USA 1999; 96:790-4.
14. Recker M, Blyuss KB, Simmons CP, et al. Immunological serotype interactions and their effect on the epidemiological pattern of dengue. Proc Biol Sci 2009; 276:2541-8.
15. Wearing HJ, Rohani P. Ecological and immunological determinants of dengue epidemics. Proc Natl Acad Sci USA 2006; 103:11802-7.
16. Thomas SJ, Endy TP. Critical issues in dengue vaccine development. Curr Op Inf Dis 2011; 24:442-50.
17. Durbin AP, Whitehead SS. Dengue vaccine candidates in development. Curr Top Microbiol Immunol 2010; 338:129-43.
18. Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012; 380:1559-1567.
19. Morrison AC, Minnick SL, Rocha C, et al. Epidemiology of dengue virus in Iquitos, Peru 1999 to 2005: interepidemic and epidemic patterns of transmission. PLoS Negl Trop Dis 2010; 4:e670.
20. Phillips I, Need J, Escamilla J, et al. First documented outbreak of dengue in the Peruvian Amazon region. Bull Pan Am Health Organ 1992; 26:201-7.
21. Hayes CG, Phillips IA, Callahan JD, et al. The epidemiology of dengue virus infection among urban, jungle, and rural populations in the Amazon region of Peru. Am J Trop Med Hyg 1996; 55:459-63.
22. Watts DM, Porter KR, Putvatana P, et al. Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic fever. Lancet 1999; 354:1431-4.
23. Forshey BM, Morrison AC, Cruz C, et al. Dengue virus serotype 4, northeastern Peru, 2008. Emerg Infect Dis 2009; 15:1815-8.
24. PAHO. Dengue: statistics and maps. http://new.paho.org/hq/index. php?option=com-content&task=blogcategory&id=1221&Itemid=2481 &lang=en. Accessed 12 February 2013.
25. Rocha C, Morrison AC, Forshey BM, et al. Comparison of two active surveillance programs for the detection of clinical dengue cases in Iquitos, Peru. Am J Trop Med Hyg 2009; 80:656-60.
26. Comach G, Blair PJ, Sierra G, et al. Dengue virus infections in a cohort of schoolchildren from Maracay, Venezuela: a 2-year prospective study. Vector Borne Zoonotic Dis 2009; 9:87-92.
27. Forshey BM, Guevara C, Laguna-Torres VA, et al. Arboviral etiologies of acute febrile illnesses in Western South America, 2000-2007. PLoS Negl Trop Dis 2010; 4:e787.
28. Lanciotti RS, Calisher CH, Gubler DJ, Chang GJ, Vorndam AV. Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reaction. J Clin Microbiol 1992; 30:545-51.
29. Kochel TJ, Watts DM, Halstead SB, et al. Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever. Lancet 2002; 360:310.
30. Liebman KA, Stoddard ST, Morrison AC, et al. Spatial dimensions of dengue virus transmission across interepidemic and epidemic periods in Iquitos, Peru (1999-2003). PLoS Negl Trop Dis 2012; 6:e1472.
31. Kuno G, Gubler DJ, Oliver A. Use of "original antigenic sin" theory to determine the serotypes of previous dengue infections. Trans R Soc Trop Med Hyg 1993; 87:103-5.
32. van Panhuis WG, Gibbons RV, Endy TP, et al. Inferring the serotype associated with dengue virus infections on the basis of preand postinfection neutralizing antibody titers. J Infect Dis 2010; 202:1002-10.
33. Roehrig JT, Hombach J, Barrett AD. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol 2008; 21:123-32.
34. Thomas SJ, Nisalak A, Anderson KB, et al. Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance. Am J Trop Med Hyg 2009; 81:825-33.
35. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. http://www. R-project.org/. Accessed 22 December 2011.
36. Halstead SB. Observations related to pathogensis of dengue hemorrhagic fever. VI. Hypotheses and discussion. Yale J Biol Med 1970; 42:350-62.
37. Sabin AB. Research on Dengue during World War II. Am J Trop Med Hyg 1952; 1:30-50.
38. Murphy BR, Whitehead SS. Immune response to dengue virus and prospects for a vaccine. Annual Rev Immunol 2011; 29:587-619.
39. Halstead SB. Dengue in the Americas and Southeast Asia: do they differ? Rev Panam Salud Publica 2006; 20:407-15.
40. OhAinle M, Balmaseda A, Macalalad AR, et al. Dynamics of dengue disease severity determined by the interplay between viral genetics and serotype-specific immunity. Sci Transl Med 2011; 3:114ra128.
41. Guzman MG, Alvarez A, Vazquez S, Alvarez M. Epidemiological studies on dengue virus type 3 in Playa municipality, Havana, Cuba, 2001-2002. Int J Infect Dis 2012; 16:e198-203.
42. Guzman MG, Kouri GP, Bravo J, Soler M, Vazquez S, Morier L. Dengue hemorrhagic fever in Cuba, 1981: A retrospective seroepidemiologic study. Am J Trop Med Hyg 1990; 42:179-184.
43. Guzman MG, Kouri GP, Valdes L, et al. Epidemiologic studies on dengue in Santiago de Cuba, 1997. Am J Epidemiol 2000; 152:793-9.
44. Morrison AC, Gray K, Getis A, et al. Temporal and geographic patterns of Aedes aegypti (Diptera: Culicidae) production in Iquitos, Peru. J Med Entomol 2004; 41:1123-42.
45. De Benedictis J, Chow-Shaffer E, Costero A, Clark GG, Edman JD, Scott TW. Identification of the people from whom engorged Aedes aegypti took blood meals in Florida, Puerto Rico, using polymerase chain reaction-based DNA profiling. Am J Trop Med Hyg 2003; 68: 437-46.
46. Egger JR, Coleman PG. Age and clinical dengue illness. Emerg Infect Dis 2007; 13:924-5.
47. Edelman R. Dengue vaccines approach the finish line. Clin Infect Dis 2007; 45(Suppl 1):S56-60.
48. Pierson TC, Fremont DH, Kuhn RJ, Diamond MS. Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe 2008; 4:229-38.
49. Anderson KB, Gibbons RV, Edelman R, et al. Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate. J Infect Dis 2011; 204:442-50.
50. Johansson MA, Hombach J, Cummings DAT. Models of the impact of dengue vaccines: A review of current research and potential approaches. Vaccine 2011; 29:5860-8.